Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP059 (Imovax Polio) in Japanese Infants
NCT01389687Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2011
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trivalent inactivated polio vaccine in poliomyelitis, sponsored by Sanofi. Primary endpoint: Seroprotection rates against polio types 1, 2 and 3. Started Jul 2011; status: completed.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT01389687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389687.